Background Amide proton transfer (APT) imaging is a chemical exchange saturation transfer (CEST) technique offering potential clinical applications such as diagnosis, characterization, and treatment planning and monitoring in glioma patients. While APT‐CEST has demonstrated high potential, reproducibility remains underexplored. Purpose To investigate whether cerebral APT‐CEST with clinically feasible scan time is reproducible in healthy tissue and glioma for clinical use at 3 T. Study Type Prospective, longitudinal. Subjects Twenty‐one healthy volunteers (11 females; mean age ± SD: 39 ± 11 years) and 6 glioma patients (3 females; 50 ± 17 years: 4 glioblastomas, 1 oligodendroglioma, 1 radiologically suspected low‐grade glioma). Field Strength/Sequence 3 T, Turbo Spin Echo ‐ ampling perfection with application optimized contrasts using different flip angle evolution ‐ chemical exchange saturation transfer (TSE SPACE‐CEST). Assessment APT‐CEST measurement reproducibility was assessed within‐session (glioma patients, scan session 1; healthy volunteers scan sessions 1, 2, and 3), between‐sessions (healthy volunteers scan sessions 1 and 2), and between‐days (healthy volunteers, scan sessions 1 and 3). The mean APT CEST values and standard deviation of the within‐subject difference (SD diff ) were calculated in whole tumor enclosed by regions of interest (ROIs) in patients, and eight ROIs in healthy volunteers—whole‐brain, cortical gray matter, putamen, thalami, orbitofrontal gyri, occipital lobes, central brain—and compared. Statistical Tests Brown‐Forsythe tests and variance component analysis (VCA) were used to assess the reproducibility of ROIs for the three time intervals. Significance was set at P < 0.003 after Bonferroni correction. Results Intratumoral mean APT CEST was significantly higher than APT CEST in healthy‐appearing tissue in patients (0.5 ± 0.46%). The average within‐session, between‐sessions, and between‐days SD diff of healthy control brains was 0.2% and did not differ significantly with each other (0.76 > P > 0.22). The within‐session SD diff of whole‐brain was 0.2% in both healthy volunteers and patients, and 0.21% in the segmented tumor. VCA showed that within‐session factors were the most important (60%) for scanning variance. Data Conclusion Cerebral APT‐CEST imaging may show good scan–rescan reproducibility in healthy tissue and tumors with clinically feasible scan times at 3 T. Short‐term measurement effects may be the dominant components for reproducibility. Level of Evidence 2 Technical Efficacy ...

Purpose To gain insight into how patients with primary brain tumors experience MRI, follow-up protocols, and gadolinium-based contrast agent (GBCA) use. Methods Primary brain tumor patients answered a survey after their MRI exam. Questions were analyzed to determine trends in patients’ experience regarding the scan itself, follow-up frequency, and the use of GBCAs. Subgroup analysis was performed on sex, lesion grade, age, and the number of scans. Subgroup comparison was made using the Pearson chi-square test and the Mann-Whitney U-test for categorical and ordinal questions, respectively. Results Of the 100 patients, 93 had a histopathologically confirmed diagnosis, and seven were considered to have a slow-growing low-grade tumor after multidisciplinary assessment and follow-up. 61/100 patients were male, with a mean age ± standard deviation of 44 ± 14 years and 46 ± 13 years for the females. Fifty-nine patients had low-grade tumors. Patients consistently underestimated the number of their previous scans. 92% of primary brain tumor patients did not experience the MRI as bothering and 78% would not change the number of follow-up MRIs. 63% of the patients would prefer GBCA-free MRI scans if diagnostically equally accurate. Women found the MRI and receiving intravenous access significantly more uncomfortable than men (p=0.003). Age, diagnosis, and the number of previous scans had no relevant impact on the patient experience. Conclusion Patients with primary brain tumors experienced current neuro-oncological MRI practice as positive. Especially women would, however, prefer GBCA-free imaging if diagnostically equally accurate. Patient knowledge of GBCAs was limited, indicating improvable patient information.

Purpose To gain insight into how patients with primary brain tumors experience MRI, follow-up protocols, and gadolinium-based contrast agent (GBCA) use. Methods Primary brain tumor patients answered a survey after their MRI exam. Questions were analyzed to determine trends in patients’ experience regarding the scan itself, follow-up frequency, and the use of GBCAs. Subgroup analysis was performed on sex, lesion grade, age, and the number of scans. Subgroup comparison was made using the Pearson chi-square test and the Mann–Whitney U-test for categorical and ordinal questions, respectively. Results Of the 100 patients, 93 had a histopathologically confirmed diagnosis, and seven were considered to have a slow-growing low-grade tumor after multidisciplinary assessment and follow-up. 61/100 patients were male, with a mean age ± standard deviation of 44 ± 14 years and 46 ± 13 years for the females. Fifty-nine patients had low-grade tumors. Patients consistently underestimated the number of their previous scans. 92% of primary brain tumor patients did not experience the MRI as bothering and 78% would not change the number of follow-up MRIs. 63% of the patients would prefer GBCA-free MRI scans if diagnostically equally accurate. Women found the MRI and receiving intravenous cannulas significantly more uncomfortable than men (p = 0.003). Age, diagnosis, and the number of previous scans had no relevant impact on the patient experience. Conclusion Patients with primary brain tumors experienced current neuro-oncological MRI practice as positive. Especially women would, however, prefer GBCA-free imaging if diagnostically equally accurate. Patient knowledge of GBCAs was limited, indicating improvable patient information.